Celgene: FDA Approves Revlimid in Combo with Rituximab for Lymphoma

Celegene said the U.S. Food and Drug Administration (FDA) approved Revlimid in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Celgene said this is the first FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin’s lymphoma that doesn’t include chemotherapy.

Approval was based on a Phase 3 study which showed the combination significantly improved median progression-free survival versus rituximab monotherapy, the company said.

https://www.marketscreener.com/CELGENE-CORPORATION-8736/news/Celgene-Says-FDA-Approves-Revlimid-in-Combination-with-Rituximab-for-Lymphoma-28668314/